Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Assets Average (2016 - 2025)

Historic Assets Average for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $420.7 million.

  • Theravance Biopharma's Assets Average rose 1717.8% to $420.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $420.7 million, marking a year-over-year increase of 1717.8%. This contributed to the annual value of $368.1 million for FY2024, which is 2559.52% down from last year.
  • As of Q3 2025, Theravance Biopharma's Assets Average stood at $420.7 million, which was up 1717.8% from $384.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Assets Average registered a high of $685.4 million during Q4 2022, and its lowest value of $348.9 million during Q1 2025.
  • Over the past 5 years, Theravance Biopharma's median Assets Average value was $397.8 million (recorded in 2023), while the average stood at $426.6 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 7622.4% in 2022, then plummeted by 4196.58% in 2023.
  • Over the past 5 years, Theravance Biopharma's Assets Average (Quarter) stood at $389.0 million in 2021, then skyrocketed by 76.22% to $685.4 million in 2022, then tumbled by 41.97% to $397.8 million in 2023, then decreased by 10.72% to $355.1 million in 2024, then rose by 18.48% to $420.7 million in 2025.
  • Its Assets Average was $420.7 million in Q3 2025, compared to $384.8 million in Q2 2025 and $348.9 million in Q1 2025.